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The application of metal nanoparticles as sensitization materials is a common strategy that is
used to study dose enhancement in radiotherapy. Recent in vitro tests have revealed that
magnetic gold nanoparticles can be used in cancer therapy under a magnetic field to enhance
the synergistic efficiency in radiotherapy and photothermal therapy. However, magnetic gold
nanoparticles have rarely been studied as sensitization materials. In this study, we obtained
further results of the sensitization properties of magnetic gold nanoparticles using the Monte
Carlo method TOPAS and TOPAS-nBio. We analyzed the properties of magnetic gold
nanoparticles in monoenergetic photons and brachytherapy, and we investigated whether the
magnetic field contributes to the sensitization process. Our results demonstrated that the dose
enhancement factor of the magnetic gold nanoparticles was 16.7% lower than that of gold
nanoparticles in a single particle irradiated by monoenergetic photons. In the cell model, the
difference was less than 8.1% in the cytoplasm. We revealed that the magnetic field has no
detrimental effect on radiosensitization. Moreover, the sensitization properties of magnetic
gold nanoparticles in a clinical brachytherapy source have been revealed for the first time.
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1. Introduction
Cancer is a serious disease that continues to threaten
human health. At present, more than 50% of cancer patients
have been treated and cured by radiotherapy [1, 2]. Although
radiotherapy can kill tumor cells, it simultaneously threatens
healthy tissues. Therefore, simulation studies on improving
the sensitivity of tumor cells to radiotherapy and minimizing
the mortality of healthy cells to enhance the efficiency of
radiotherapy can provide a theoretical basis for promoting
the clinical application of radiotherapy.
With the rapid developments in biotechnology and
nanotechnology, the use of nanomaterials as
radiosensitization materials offers new possibilities for
cancer radiotherapy [3, 4, 5]. Nanoparticles (NPs) congregate
in tumors as a result of enhanced permeability and retention
(EPR) [6, 7]. In radiotherapy, high atomic number (Z)
materials can be used to enhance the dose in tumors in
combination with the EPR property. Gold
Nanoparticles (AuNPs) have exhibited high X-ray cross
section, low toxicity, good biocompatibility, and easy
synthesis, thereby attracting significant attention in research
on the radiation sensitization of nanomaterials in recent years.
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AuNPs have the potential to be applied to medical imaging,
medical drug delivery, photothermal therapy, and radiation
sensitization therapy. In 2004, Hainfeld [8] demonstrated the
radiation dose enhancement effect of AuNPs through animal
experiments, which laid the foundation for research on
AuNPs in radiation sensitization.
Recent advances have revealed the high potential of
targeted magnetic NPs in radiotherapy [9], whereby a
magnetite core combined with a suitable coating can be
bestowed with biochemical and drug-delivery properties [10].
For this reason, a magnetite core combined with a gold shell
was proposed to improve the stabilization, biocompatibility,
and surface reactivity of sensitizing NPs [11].
The Monte Carlo (MC) method [12] is a computational
approach that represents physical processes by simulating
numerous random particles. Commonly used MC codes
include Geant4, MCNP, and Fluka, which have a high
calculation efficiency. Among these, the Geant4-DNA
extension package can be used to simulate the interaction of
eV energy electrons. This package has attracted the attention
of medical physicists owing to its user-friendly operation
interface in the form of TOPAS. TOPAS-nBio is an
extension of TOPAS that is based on and extends the Geant4
Simulation Toolkit for radiobiology applications [13]. Since
2020, human lives have changed dramatically as a result of
the COVID-19 pandemic. In 2021, Francis [14] investigated
the influence of ionizing radiation on SARS-CoV-2 using
Geant4-DNA, thereby providing a new concept for the
production of an inactivated vaccine, which is still being
developed at present, and revealing the extensive application
prospects and significant potential of the MC method.
Nevertheless, magnetic gold nanoparticles have rarely
been studied as sensitization materials. To address this
limitation, in this study, we used TOPAS [15, 16] and
TOPAS-nBio [17] to study the Fe3O4@AuNP properties in
radiotherapy sensitization compared to an AuNP in a single
nanoparticle and a cell model using monoenergetic photons.
Subsequently, we combined the simulation with a magnetic
field to investigate the influence on the sensitivity process.
Finally, we changed the photon beams with a brachytherapy
source to perform the same process. Our work contributes to
the research on Fe3O4@AuNPs in radiotherapy using the MC
method and provides a reference for clinical research.
2. Materials and methods
2.1 Cell uptake of Fe3O4@AuNPs by HeLa cells with or
without magnetic field
The Fe3O4@AuNP that was used in the test of Hu [18]
consisted of a Fe3O4 core and a gold shell, as shown in Fig.
1(a). The mean diameter of the Fe3O4@AuNPs was 100 nm
according to dynamic light scattering analysis, as illustrated
in Fig. 1(b). According to Figs. (a) and (b), we obtained that
the Fe3O4@AuNP consisted of a 60 nm diameter Fe3O4 core
and a 20 nm thickness gold shell. Therefore, we selected 100
nm as the diameter of the Fe3O4@AuNP and used the same
Fe3O4 and Au ratio in our simulation work. Hu used confocal
laser scanning microscopy (CLSM) to observe the
distribution of the Fe3O4@AuNPs internalized by the HeLa
cells, as depicted in Fig. 1(c). The Fe3O4@AuNPs and
lysosomes were labeled by fluorescein isothiocyanate and
LysoTracker Red, and exhibited green and red fluorescence,
respectively, in the CLSM. The distributions of the
Fe3O4@AuNPs and lysosomes were clearly partially
overlapped. It meant the Fe3O4@AuNPs were internalized by
cells and could be swallowed by the lysosomes in the
cytoplasm. We also observed that the green fluorescence
intensity with a 0.2 T magnetic field was higher than that
without a magnetic field. Hu used flow cytometry to analyze
the mean fluorescence intensity to compare the cell uptake of
Fe3O4@AuNPs with and without a magnetic field
quantitatively, as illustrated in Fig. 1(d). The results
demonstrated that the fluorescence intensity of the
Fe3O4@AuNPs in an external magnetic field was 1.48 times
higher than that without a magnetic field. Moreover, Hu
demonstrated that Fe3O4@AuNPs can be used to decrease
the viability of HeLa cells in radiotherapy with an external
magnetic field (0.2 T). The results indicated that the cell
viability was affected by the magnetic field owing to the cell
uptake properties being enhanced under the magnetic field.
In fact, the cell viability may be affected by the cell uptake
properties, the physical dose enhancement of Fe3O4@AuNPs,
and other conditions. In our research, we studied the dose
enhancement properties of Fe3O4@AuNPs with and without
a magnetic field using TOPAS and TOPAS-nBio.
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Figure 1. (a) TEM image of Fe3O4@AuNPs. (b) Dynamic light scattering analysis of Fe3O4@AuNPs. (c) Distribution of Fe3O4@AuNPs in
HeLa cells with and without magnetic field in CLSM after 3 h of incubation. (d) Fluorescence intensity of Fe3O4@AuNPs with and without
magnetic field.
2.2 Calculation methods for dose enhancement factor:
two-step and one-step methods
Two methods are used for calculating the dose
enhancement factor (DEF) with TOPAS and TOPAS-nBio.
Lin [19] investigated the dose enhancement of proton and
photon irradiation on AuNPs using TOPAS. Lin calculated
the dose distribution around a single AuNP that changed with
the distance from the particle surface and obtained the
distribution of the DEF at different distances from the AuNP
surface. The DEF is defined as the ratio of the dose deposited
around the metal nanoparticle (MNP) and water nanoparticle
(WNP). As the Geant4-DNA physics processes are workable
in water only, this package cannot be used to calculate the
tracks in AuNP accurately; thus, Lin divided the dose
calculation into two steps. First, the physics module
Penelope was activated to calculate the interaction between
the particle source and AuNP in water, following which the
generated secondary electrons that were excited from the
AuNP surface were stored in the phase space file. Second,
the phase space file was placed into a water box to calculate
the dose distribution of the secondary electrons in water and
Geant4-DNA was activated in the water box region. Such a
method of calculating the DEF is referred to as the "two-step
method" in our research. However, the surface dose
distribution around a single AuNP is not the exclusive factor
affecting the cell livability, and the effects of the radiation
emerging or scattering from an AuNP on the other AuNPs in
a cell model should also be considered.
Scientists developed TOPAS-nBio to simulate
radiobiological experiments on nanometer scale cells
considering the physics, chemistry, and biology effects.
TOPAS-nBio supports the assignment of different physical
models to different geometry components. Rudek [20]
established the AuNPs that were internalized in a cell model
irradiated by photons, protons, and carbon ions respectively
using TOPAS-nBio. To define suitable physical modules in
different regions, Rudek set the Livermore physical process
in the AuNP region and the Geant4-DNA process outside the
AuNP region. Thereafter, the DEFs in the cytoplasm and
nucleus were calculated. This method of calculating the DEF
is referred to as the "one-step method" in this work.
The two methods mentioned above are aimed at a single
nanoparticle and a single cell. A single cell includes the
physical interaction between the primary beam and MNPs.
Therefore, in the simulation study of Fe3O4@AuNPs, we
considered the calculation results of both the two-step and
one-step method to evaluate the sensitivity enhancement
performance in a single nanoparticle as well as in a cell. To
compare the two-step method and one-step method, we
modeled the same geometry to simulate the interaction
process of the photons and AuNP in water, as illustrated in
Fig. 2 (a).
Figure 2. Geometry sketch of MC simulation (not the actual scale): (a) A 100 nm diameter AuNP was placed in a 20 μm diameter sphere
filled with water. A photon beam with the same size as the AuNP in diameter was placed upstream to the AuNP. The dose was scored in
the grids with a volume size of 1 × 1 × 1 nm3 for 0 to 150 nm, 10 × 10 × 10 nm3 for 150 nm to 1.95 μm, and 100 × 100 × 100 nm3 for 1.95
μm to 19.95 μm from the AuNP surface. (b) The 10 μm diameter water sphere contained a 5 μm water sphere in the center to model the cell
containing a nucleus. The 100 nm diameter NPs were randomly distributed in the cytoplasm. The photon beam had the same diameter as
the cell and was placed upstream to the cell.
For the two-step method, we divided the simulation into
two steps, as described above. In the first step, the AuNP was
placed in a box (100 × 100 × 100 nm3) filled with vacuum
and irradiated by a 50 keV photon beam, following which the
output electron phase space file was obtained from the AuNP
surface. In the second step, the electron phase space file was
used as a particle source and placed in the center of the water
sphere (20 μm diameter). The deposited dose was scored in
the grids from 0 to 150 nm, 150 nm to 1.95 μm, and 1.95 μm
to 19.95 μm from the AuNP surface with different precisions.
We set the Livermore physics processes for the first step and
the Geant4-DNA physics for the second step. The de-
excitation was activated to include Auger production and
particle induced X-ray emission.
In the one-step method, the AuNP was placed in the center
of the water box (20 μm diameter). Thereafter, the 50 keV
photon beam interacted with the AuNP and the dose was
recorded at different distances from the AuNP surface. The
AuNP region was assigned with Livermore physics processes,
whereas all of the other regions were set with Geant4-DNA
physics processes. In both methods, we recorded the dose
distribution that was produced by the electrons and photons
to investigate which particle types mainly contributed to the
deposited dose.
2.3 Photon energy dependence of single
Fe3O4@AuNP dose enhancement using two-step
method
We used an Fe3O4@AuNP with the same size and
composition as in Hu’s test in our simulation. Five
monoenergetic photon beams (50, 100, 150, 200, and 250
keV) were used as particle sources to irradiate the single
Fe3O4@AuNP, AuNP, and WNP. The photon source was
plane parallel with a 100 nm diameter and started at the
nanoparticle surface, as illustrated in Fig. 2(a). To evaluate
the properties of the Fe3O4@AuNP at different photon
energies, we compared the DEFs of the Fe3O4@AuNP and
AuNP that were irradiated by the same five monoenergetic
photon beams with the same simulation parameters.
2.4 Photon energy and Nanoparticles
concentration dependence of cell dose
enhancement using one-step method
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The radiation processes were implemented in a simplified
cell model. The 10 μm diameter cell contained a 5 μm
diameter nucleus in the center and the cell was placed in a
water box. Both the cytoplasm and nucleus were filled with
water to model the cellular environment. The monoenergetic
photon source (50, 100, 150, 200, and 250 keV) was plane
parallel with a 10 μm diameter and started from the cell
surface, as illustrated in Fig. 2(b). Considering that NPs are
predominantly dispersed in the cytoplasm when NPs enter
the cell [21], the 100 nm diameter Fe3O4@AuNPs and 100
nm diameter AuNPs were placed in the cytoplasm randomly
respectively in the simulation to draw a comparison. To
cover the desired dose range on the cell level, the NPs mass
concentration was incremented in the range of 1 to 50
mg/mL [22]. Subsequently, we selected 1, 5, 10, and 50
mg/mL as the concentration weights of the Fe3O4@AuNPs
and AuNPs in the cytoplasm. The corresponding NPs
numbers are listed in Table 1.
Table 1. Number of 10 μm diameter Fe3O4@AuNPs and AuNPs in
cytoplasm for five concentration weights (units: mg/mL).
Mass/volume
(mg/mL)








52 259 518 2588
2.5 Magnetic field dependence of single
nanoparticle and cell dose enhancement
With the increasing use of MRI-guided radiotherapy, it is
necessary to investigate the influence of the magnetic field
on the radiotherapy. The in vitro tests performed by Hu [18]
demonstrated that core-shell Fe3O4@AuNPs can be used to
decrease the viability of HeLa cells by improving their
internalization by the cells in an external magnetic field (0.2
T). Bug [23] and Lazarakis [24] demonstrated that the
magnetic field affected the charged particle trajectory only;
the physical cross section, DNA strand breaks, and cluster
size distribution could not be changed by the magnetic field
in Geant4.
Scientists have shown that magnetic targeting is a
promising technology among passive tumor accumulation in
radiotherapy. Magnetic NPs can be focused on the tumors
under the magnetic field outside the body [25]. However, the
magnetic targeting property for magnetic material in a
magnetic field cannot be simulated with the MC method.
Therefore, we used four concentrations of Fe3O4@AuNPs to
simulate the targeting focus of the Fe3O4@AuNPs in four
magnetic fields, as discussed in section 2.4.
We investigated the influence of the changed particle
trajectory under the magnetic field on the sensitization
process of the Fe3O4@AuNP and AuNP. The simulation was
performed on a single nanoparticle and a cell model using the
two-step and one-step methods, with irradiation by a 50 keV
monoenergetic photon beam. The models used were the same
as those described in sections 2.3 and 2.4. An external
magnetic field with a strength of 0.1 to 2 T was used in the
simulations. The NPs concentration was 50 mg/mL in the
cell model.
2.6 DEFs of Fe3O4@AuNP and AuNP interacted
with brachytherapy source
In the in vitro tests of Hu [18], the HeLa cells were
irradiated by photons from a Varian linear accelerator (True
Beam). In this study, we further evaluated the sensitization
properties of the Fe3O4@AuNP and AuNP under a clinically
applied source. We implemented the Varian GammaMed
Plus HDR 192Ir brachytherapy source model [26] using
TOPAS to explore the DEF of the Fe3O4@AuNP irradiated
by a brachytherapy source. The particle numbers that were
emitted from the brachytherapy source model per keV for the
per initial photons, which were recorded on a parallel plane
at a 2 cm distance from the source center, are presented in
Fig. 3. A total of 108 initial photons were used as the source
beam and the source was placed in an 80 × 80 × 80 cm3
water box to calculate the dose distribution in water. With
the exception of the radiation source, all parameters were
consistent with those described in section 2.5.
6
Figure 3. Particle energy spectra emitted from brachytherapy source model, recorded on parallel plane at 2 cm distance from source center.
3. Results
3.1 Comparison of two-step and one-step
methods
Figure 4 presents the results of the comparison between
the one-step and two-step methods as well as the dose
contributions from the electrons and photons. It is obvious
that the four curves in Fig. 4 exhibit similar trends. The
results reveal two significant conclusions. First, the deposited
dose was mainly contributed by the secondary electrons. The
dose produced by the photons was very slight compared to
the electrons in both the one-step and two-step methods.
According to the results, only the electrons need to be
considered in irradiation simulation to improve the
calculation efficiency, regardless of whether the one-step or
two-step method is used. Second, the dose distributions of
the one-step and two-step methods exhibited no significant
differences. Thus, we can use the two-step method to
calculate the DEF around a single nanoparticle and the one-
step method to calculate the DEF in a cell model. Moreover,
the influence of the two methods on the simulation results
does not need to be considered.
Figure 4. Dose distribution per incident photon vs. distance from
AuNP surface.
3.2 Photon energy dependence of single
Fe3O4@AuNP dose enhancement
The results of the photon irradiations are depicted in Fig. 5.
Figures 5(a), (b), and (c) present the dose distributions at
different distances from the surface of the single
Fe3O4@AuNP, single AuNP, and single WNP, respectively,
per incident photon. It is clear that the five dose distribution
curves in both Figs. 5(a) and (b) exhibited similar trends.
Higher energy of the photon led to a higher dose distribution
in the energy range from 150 to 250 keV. However, the
deposited dose of the 100 keV photon was higher than 50
keV within the range of 1.3 × 103 to 7×103 nm. According to
Fig. 5(c), the 100 keV photon dose distribution was higher
than that of the 50 keV photon in the range of 1 × 103 to 1.4
7
× 104 nm. The DEFs of the Fe3O4@AuNP and AuNP were
calculated based on Figs. 5(a), (b), and (c) and the results are
plotted in Figs. 5(d) and (e). The five curves in Figs. 5(d) and
(e) also exhibited similar trends. The DEFs of both NPs
increased with an increase in the photon energy for the 150,
200, and 250 keV photons. The curves of the 50 and 100 keV
photons crossed at 103 and 1.8 × 104 nm. To compare the
total dose deposition in the range of 1 to 2 × 104 nm
intuitively, the doses that were distributed at different
distances were totaled for each photon energy, as illustrated
in Fig. 5(f). According to the figure, the DEF of the
Fe3O4@AuNP was 16.7% lower than that of the AuNP on
average. Moreover, the peak of the DEF verus photon energy
curve appeared at 100 keV. For thousands of keV energy
photons irradiated with Fe3O4@AuNP and AuNP, the DEF
was the highest near 100 keV.
Figure 5. Relationship between dose distribution per incident photon and distance from surface of (a) Fe3O4@AuNP, (b) AuNP, and (c)
WNP for 50, 100, 150, 200, and 250 keV photons. DEF distributions around (d) Fe3O4@AuNP and (e) AuNP as function of distance from
the nanoparticle surface. (f) Total DEF around Fe3O4@AuNP and AuNP in range of 1 to 2 × 104 nm vs. photon energy.
3.3 Photon energy and Nanoparticles
concentration dependence of cell dose
enhancement
The DEFs of the Fe3O4@AuNPs and AuNPs in the
cytoplasm and nucleus are presented in Figs. 6(a) and (b),
respectively. In the cytoplasm, the DEFs of the
Fe3O4@AuNPs and AuNPs decreased with an increase in the
photon energy. The maximum DEFs of the Fe3O4@AuNPs
and AuNPs for 50 mg/mL were 3.69 and 3.83. The
maximum difference was within 2.1%, 1%, 2.2%, and 8.1%
when comparing the DEFs of the AuNPs and the
Fe3O4@AuNPs for the 1, 5, 10, and 50 mg/mL NPs
concentrations, respectively. In the nucleus, the DEF of the
AuNPs reached the maximum at 100 keV with the 5, 10, and
50 mg/mL weight concentrations and 50 keV with 1 mg/mL.
The maximum difference was within 1.9%, 5%, 13%, and
3.1% when comparing the AuNPs and Fe3O4@AuNPs for the
1, 5 , 10, and 50 mg/mL NP concentrations, respectively.
The DEF differences between the Fe3O4@AuNPs and
AuNPs in the cytoplasm and nucleus are summarized in
Table 2. It can be observed that the energy had a greater
influence on the DEF when the particle concentration was
higher. In the cytoplasm, the DEF of the AuNPs was higher
than that of the Fe3O4@AuNPs except for 1 mg/mL.
However, the difference was not obvious in the nucleus.
Furthermore, in general, a higher NPs concentration led to a
higher DEF in the cytoplasm and nucleus. This means that
the high magnetic focus property can achieve better dose
enhancement for radiotherapy.
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Figure 6. Function of DEF and photon energy in (a) cytoplasm and (b) nucleus.




Concentration in weight (mg/mL)
1 5 10 50 1 5 10 50
DEF differences between AuNPs and Fe3O4@AuNPs in cytoplasm (%) DEF differences between AuNPs and Fe3O4@AuNPs in nucleus (%)
50 -0.16 0.68 0.90 3.51 0.34 2.67 1.53 0.87
100 0.19 0.41 2.11 8.09 1.45 4.91 4.56 3.09
150 -2.05 0.98 1.46 3.74 -0.50 -1.40 7.35 -2.04
200 -1.09 1.00 1.76 4.19 -1.88 0 12.54 -1.45
250 -0.65 0.15 -0.03 2.36 0.98 0.67 7.43 -1.71
3.4 Magnetic field dependence of dose
enhancement
The relationship between the magnetic field and DEF of
the NPs is presented in Figs. 7 and 8. We used the two-step
method on a single nanoparticle and found that the DEF of
the AuNP was 15% higher than that of the Fe3O4@AuNP
under the magnetic field, as illustrated in Fig. 7. The DEF
was stable above 0.5 T and the value was slightly higher than
the DEF without a magnetic field. The minimum DEF value
appeared at 0.2 T and this was 2.5% lower than the constant
value. This simulation result indicates that the magnetic field
did not contribute significantly to the DEF.
The DEFs of the AuNP and Fe3O4@AuNP in the
cytoplasm and nucleus are illustrated in Fig. 8. We used the
one-step method in a cell to simulate the influence of the
magnetic field on the DEF. The Fe3O4@AuNP DEF was
3.9% and 3.1% lower than that of the AuNP in the cytoplasm
and nucleus, respectively. The DEF in the cytoplasm was
11.7% and 12.4% higher than that in the nucleus for the
Fe3O4@AuNP and AuNP. In general, the magnetic field did
not contribute significantly to the DEF in the cell model. In
this study, we concluded that a magnetic field with a strength
of 0.1 T to 2 T would not have a negative effect on the
sensitization process.
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Figure 7. Relationship between magnetic field and DEF of a single Fe3O4@AuNP and AuNP.
Figure 8. Relationship between magnetic field and DEF of Fe3O4@AuNPs and AuNPs in cytoplasm and nucleus.
3.5 DEFs of Fe3O4@AuNP and AuNP irradiated by
brachytherapy source
The results of the brachytherapy source irradiations are
depicted in Fig. 9. For the single nanoparticle model in Fig.
9(a), the DEF of the Fe3O4@AuNP was 9.26% lower than
that of the AuNP. For the cell model in Fig. 9(b), the DEFs
of the Fe3O4@AuNP were 6.3% and 2.7% lower than those
of the AuNP in the cytoplasm and nucleus, respectively,
whereas the DEFs of the Fe3O4@AuNP and AuNP in the
cytoplasm were 26.75% and 31.62% higher than those in the
nucleus.
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Figure 9. Total DEF of Fe3O4@AuNP and AuNP in (a) single nanoparticle in range of 1 to 2 × 104 nm, and (b) in cytoplasm and nucleus
when irradiated by brachytherapy source.
4. Discussion
AuNPs are studied extensively in radiosensitization owing
to their properties of high X-ray absorption, hypotoxicity,
and easy synthesis. Magnetite can be used as targeting
material to improve tumor drug delivery because of the
magnetic targeting property in the magnetic field [25]. As a
novel nanoparticle, the Fe3O4@AuNP combines the
properties of gold and magnetite, and it has been used in in
vitro experiments to decrease the cell survival rate [18].
In this study, we explored the DEF of an Fe3O4@AuNP in
a single nanoparticle and in a cell model compared to the
AuNP. The DEF around the single Fe3O4@AuNP was 16.7%
lower than that of the AuNP, and the differences between the
AuNP and Fe3O4@AuNP in the cytoplasm and nucleus are
detailed in Table 2. With the increase in the NPs
concentration, the DEF residuals between the Fe3O4@AuNPs
and AuNPs increased in the cytoplasm. It was expected that
the DEF of the Fe3O4@AuNP would be lower than that of
the AuNP because the photoelectric cross section of iron and
oxygen is lower than that of gold. We quantified the
discrepancy between the Fe3O4@AuNP and AuNP to provide
an analysis of core-shell magnetic NPs that are used as
sensitivity materials. It is well known that the clustering
property of AuNPs will decrease the DEF in a cell in
radiotherapy. However, little research has been conducted on
how to avoid magnetic NP clustering. Significant analytical
potential exists for improving the magnetic NPs stability by
modifying the extra magnetic field so as to increase the DEF.
We investigated the influence of the magnetic field on the
DEF and demonstrated that the magnetic field did not have a
significant effect on the sensitization process. The results
revealed that the changed electron trajectory was insufficient
to influence the dose enhancement, or the electron trajectory
was insufficient to be changed with such electron energy and
the magnetic field [23]. Therefore, the magnetic field would
not risk physical enhancement because the electron energy
was too high according to the magnetic field. Combined with
the in vitro experiment carried out by Hu, we verified that the
radiosensitization mainly benefited from the physical
enhancement of Fe3O4@AuNP in addition to the cell uptake
in the magnetic field.
Furthermore, we constructed a brachytherapy source for
irradiation with a single nanoparticle and a cell model. The
results of the brachytherapy irradiation showed the residuals
between the Fe3O4@AuNP and AuNP in a single
nanoparticle and a cell model. The DEF differences between
the AuNP and Fe3O4@AuNP were 9.26%, 6.3%, and 2.7%
for the single particle, cytoplasm, and nucleus, respectively.
The results clarified the dose enhancement of the
Fe3O4@AuNPs under the brachytherapy source. In the future,
research on guiding the Fe3O4@AuNPs to focus on tumors
through the magnetic field will be quite beneficial. For
example, the source applicator may be magnetized to guide
magnetic NPs or the sensitization may be combined with
MRI-guided brachytherapy to focus the magnetic NPs. This
research may raise concerns regarding MRI-guided
brachytherapy combined with magnetic NPs.
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5. Conclusions
In this work, we compared the one-step and two-step
methods for calculating the DEF to verify that there was no
significant difference between the methods. Thereafter, we
applied the two methods to a single particle and a cell model
to investigate the DEFs of the Fe3O4@AuNP and AuNP. The
DEF of the Fe3O4@AuNP was 16.7% lower than that of the
AuNP in a single particle. In the cell model, the DEF
difference between the Fe3O4@AuNP and AuNP was below
8.1% in the cytoplasm with an NPs concentration of 1 to 50
mg/mL. We also demonstrated that the magnetic field has no
detrimental effect on the NPs radiosensitization. Furthermore,
we applied a brachytherapy source for interaction with the
Fe3O4@AuNP and AuNP in a single nanoparticle and a cell
model to obtain the DEF in brachytherapy source irradiation.
In summary, this study has revealed the Fe3O4@AuNP
properties in radiotherapy dose enhancement using the MC
method for the first time. Moreover, we demonstrated that
the physical dose enhancement of the Fe3O4@AuNP is
independent of the magnetic field. Finally, we determined the
DEF of Fe3O4@AuNPs in a brachytherapy source to provide
simulation results for clinical research. In future research,
Fe3O4@AuNPs may be combined with a magnetic field
(such as MRI) to overcome the challenge of NPs clustering
and to improve the NPs concentration in the cell. This will be
desirable for future in vitro tests on radiosensitization as well
as clinical research.
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